Exploring Inhibitor Binding at the S′ Subsites of Cathepsin L

Citations Over Time

Abstract

We report a series of noncovalent, reversible inhibitors of cathepsin L that have been designed to explore additional binding interactions with the S' subsites. The design was based on our previously reported crystal structure that suggested the possibility of engineering increased interactions with the S' subsites ( Chowdhury et al. J. Med. Chem. 2002, 45, 5321-5329 ). A representative of these new inhibitors has been co-crystallized with mature cathepsin L, and the structure has been solved and refined at 2.2 A. The inhibitors described in this work extend farther into the S' subsites of cathepsins than any inhibitors reported in the literature thus far. These interactions appear to make use of a S3' subsite that can potentially be exploited for enhanced specificity and/or affinity.

Related Papers

• → Cysteine cathepsins and extracellular matrix degradation(2014)337 cited
• → The Future of Cysteine Cathepsins in Disease Management(2017)186 cited
• → Cystatin C and cathepsins in cardiovascular disease(2008)32 cited
• → Molecular probes for selective detection of cysteine cathepsins(2021)18 cited
• → Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I)(2004)62 cited